The numbers released by the World Health Organization this week are not a plateau — they are a trajectory. Since the outbreak was declared in mid-May, the Democratic Republic of Congo has recorded 1,561 confirmed Ebola cases and 506 confirmed deaths. The WHO has stated plainly that the outbreak remains in an "expansion phase," meaning the worst is not behind anyone. Two fatalities have also been confirmed across the border in Uganda, signaling the kind of cross-border bleed that transforms a national health emergency into a regional one.

What makes this outbreak categorically different from the better-known 2014–2016 West Africa epidemic — and from the more recent outbreaks in eastern DRC that killed thousands between 2018 and 2020 — is the strain. This is Bundibugyo ebolavirus, a species first identified in Uganda in 2007. The vaccines and monoclonal antibody treatments that were deployed with meaningful effect against the Zaire strain have no approved equivalents for Bundibugyo. The international medical community is not holding back an arsenal. There largely isn't one.

That gap is now being tested in real time. A clinical trial for Galidesivir, a broad-spectrum antiviral developed by BioCryst Pharmaceuticals, has received regulatory clearance to operate within the outbreak zone — a first for this drug in an Ebola context. It is a promising signal, but a trial is not a treatment. Patients enrolled in a study are not the same as a population with access to a proven therapy, and the distinction matters enormously when a disease with a case fatality rate that can exceed 40 percent is actively spreading through communities that were already medically underserved before the first case was confirmed.

Ituri Province, in northeastern DRC, is the geographic heart of the outbreak. It is one of the most conflict-affected regions on the continent, where years of violence between armed groups and Congolese security forces have gutted healthcare infrastructure, eroded community trust in outside institutions, and complicated the logistics of any sustained response. Ebola contact tracing — the labor-intensive process of identifying everyone who may have been exposed — requires stable access, willing communities, and trained personnel who feel safe enough to show up. In Ituri, none of those conditions can be taken for granted.

Health workers, the people absorbing the direct human cost of the response, have threatened strike action over unpaid wages and inadequate protective equipment — a crisis within the crisis that the WHO has acknowledged without yet resolving. It is a pattern with grim precedent: during the 2018–2020 Kivu outbreak, attacks on treatment centers and healthcare worker deaths were among the defining features of a response that took nearly two years to bring to an end. Burning out or losing the workers who staff isolation units does not slow an Ebola outbreak. It accelerates one.

A French medical worker who contracted Ebola while working in the DRC has since recovered after evacuation and treatment in Europe — a reminder that for those with access to advanced critical care, survivable outcomes are possible. Ebola is not uniformly fatal when treated aggressively. The problem is that aggressive critical care is precisely what the healthcare infrastructure in Ituri cannot consistently provide, and evacuating thousands of local patients to European ICUs is not a public health strategy.

The regional dimension is worth watching closely. Uganda has managed previous Ebola incursions with speed and relative competence, drawing on institutional memory from the 2000 Gulu outbreak and subsequent smaller events. But a sustained source of transmission next door is a sustained threat. The Ugandan government has activated its emergency protocols, and cross-border surveillance has been intensified — but the border between the DRC and Uganda is long, porous, and crosses through communities that do not organize their lives around national lines.

The international response funding picture remains opaque. The DRC has been the site of so many overlapping crises — the world's largest ongoing displacement crisis, mpox, cholera, armed conflict — that donor fatigue is not hypothetical. It is documented. Whether the global health architecture can sustain focused attention on a strain for which it has no licensed tool, in a province where security constrains operations, against a case count that is still climbing, is the real question underneath every press release. The WHO calling it an expansion phase is not an abstraction. It is a warning.